The Use of Topical Ruxolitinib 1.5% Cream in Frontal Fibrosing Alopecia: A Case Report

    May 2024 in “ JAAD Case Reports ”
    Deesha Desai, Ambika Nohria, Kristen Lo Sicco, Jerry Shapiro
    Studysummary This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia Journal of the American Academy of Dermatology · 2024
    2. Janus Kinase Inhibition for the Treatment of Refractory Frontal Fibrosing Alopecia: A Case Series and Review of the Literature JAAD Case Reports · 2023
    3. Frontal Fibrosing Alopecia: Efficacy of Treatment Modalities International Journal of Women's Health · 2019
    4. Frontal Fibrosing Alopecia and Vitiligo: Coexistence or True Association Skin Appendage Disorders · 2016

    Related research 1

    1. Erosive Pustular Dermatosis of the Scalp: Causes and Treatments International Journal of Dermatology · 2020